Iovance Biotherapeutics Grants Stock Options to New Employees
Iovance Biotherapeutics has issued stock options to fifty new employees under its inducement plan, amounting to a total of 297,600 shares.
Overview of Stock Option Grant
On April 17, 2025, Iovance Biotherapeutics, Inc. announced the grant of inducement stock options for 297,600 shares of common stock to fifty new non-executive employees, as part of its Amended and Restated 2021 Inducement Plan. These stock options have an exercise price of $3.06 and will vest over three years—one-third will vest after the first year of employment, with the rest vesting quarterly thereafter. This grant aligns with Iovance’s strategy to innovate and develop therapies using tumor-infiltrating lymphocytes (TIL) for cancer treatment, building on its success with FDA-approved products like Amtagvi®.
Potential Benefits
- Granting stock options to fifty new employees may improve employee retention and motivation.
- The exercise price of $3.06 reflects the company’s stock price on the grant date, which aligns the interests of employees and shareholders.
- Vesting over three years promotes long-term commitment and stability in the workforce.
- Iovance’s continued development of TIL therapies underlines its dedication to advancing cancer treatment and strengthening its market position.
Potential Concerns
- The issuance of stock options could lead to scrutiny regarding the company’s compensation strategy and potential dilution of existing shareholder value.
- Frequent amendments to the inducement plan might signal difficulties in attracting and retaining top talent, perceived as instability.
- Uncertainties in commercialization and regulatory approval processes for their therapies may affect investor confidence.
Frequently Asked Questions
What is Iovance Biotherapeutics focused on?
Iovance Biotherapeutics specializes in developing innovative tumor-infiltrating lymphocyte (TIL) therapies for cancer treatment.
How many employees received stock options recently?
Fifty new non-executive employees received inducement stock options covering 297,600 shares.
What is the exercise price of the stock options granted?
The exercise price for the granted stock options is $3.06 per share, reflecting Iovance’s closing stock price on the date of grant.
What is the vesting schedule for stock options at Iovance?
The stock options vest over three years, with one-third becoming available after the first anniversary and remaining installments occurring quarterly.
Why is Amtagvi® significant for Iovance?
Amtagvi® represents the first FDA-approved T cell therapy for a solid tumor indication, marking a significant breakthrough in cancer treatment.
Disclaimer: This content summarizes a press release from GlobeNewswire and may contain inaccuracies. See the full release here.
$IOVA Insider Trading Activity
Insiders of $IOVA have engaged in a total of 1 trade in the open market over the past six months, consisting of 0 purchases and 1 sale.
Here’s a summary of the recent insider trading activity for $IOVA:
- RYAN D MAYNARD sold 50,000 shares for an estimated $503,000.
For detailed insider transaction tracking, visit Quiver Quantitative’s insider trading dashboard.
$IOVA Hedge Fund Activity
In the most recent quarter, 143 institutional investors have increased their holdings in $IOVA, while 120 reduced their positions.
Here are some notable institutional moves:
- PERCEPTIVE ADVISORS LLC sold 4,505,443 shares (-16.9%) in Q4 2024, worth approximately $33,340,278.
- MAN GROUP PLC purchased 2,414,996 shares (+inf%) in Q4 2024, valued at around $17,870,970.
- UBS GROUP AG added 2,082,340 shares (+334.7%) in Q4 2024, totaling about $15,409,316.
- BLACKROCK, INC. acquired 1,992,367 shares (+9.3%) in Q4 2024, with an estimated value of $14,743,515.
- SOLEUS CAPITAL MANAGEMENT, L.P. reduced their holdings by 1,968,500 shares (-23.1%) in Q4 2024, worth approximately $14,566,900.
- MORGAN STANLEY increased their position by 1,811,265 shares (+84.3%) in Q4 2024, valued at around $13,403,361.
- BANK OF AMERICA CORP /DE/ cut their holdings by 1,709,420 shares (-69.7%) in Q4 2024, entailing a decrease of approximately $12,649,708.
For insights on hedge fund portfolios, explore Quiver Quantitative’s institutional holdings dashboard.
$IOVA Analyst Ratings
In recent months, Wall Street analysts have provided insights on $IOVA. One firm issued buy ratings, while no firms have issued sell ratings.
Here are some of the latest analyst ratings:
- UBS issued a “Buy” rating on October 24, 2024.
To monitor analyst ratings and price targets for $IOVA, visit Quiver Quantitative’s $IOVA forecast page.
$IOVA Price Targets
Recently, several analysts have set price targets for $IOVA. Two analysts have given targets within the last six months, with a median target at $12.25.
Here are recent target updates:
- Joseph Catanzaro from Piper Sandler has a target price of $7.50 as of January 31, 2025.
- David Dai from UBS set a target price of $17.00 on October 24, 2024.
Complete Release
SAN CARLOS, Calif., April 18, 2025 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (“Iovance” or the “Company”), a biotechnology firm focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on April 17, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 297,600 shares of Iovance’s common…
Iovance Biotherapeutics Expands Workforce with New Equity Awards
Iovance Biotherapeutics, Inc. has granted stock options to fifty new non-executive employees as part of its ongoing effort to expand its workforce.
Details of the Stock Options Granted
The stock options were issued under Iovance’s Amended and Restated 2021 Inducement Plan. This plan, adopted on September 22, 2021, and subsequently amended on January 12, 2022, March 13, 2023, February 26, 2024, and November 22, 2024, allows for equity awards to be granted to new hires by the Company’s compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option mentioned in this announcement has an exercise price of $3.06, reflecting the closing price of Iovance’s common stock on the Date of Grant. The options will vest over a three-year period, with one-third of the shares becoming available on the first anniversary of each employee’s start date (the “First Vesting Date”). The remaining shares will become vested in eight quarterly installments over the subsequent two years, contingent upon continued employment during the applicable vesting periods.
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc. is focused on leading the innovation, development, and delivery of tumor infiltrating lymphocyte (TIL) therapies for cancer patients. The company aims to transform cancer treatment by utilizing the human immune system’s capability to identify and eradicate a variety of cancer cells specific to each patient. Iovance’s TIL platform has exhibited promising clinical outcomes across several solid tumors. Notably, Iovance’s Amtagvi® is recognized as the first FDA-approved T cell therapy for a solid tumor indication. The company remains dedicated to continuous innovations in cell therapy, including advancements in gene-edited cell therapies aimed at improving survival outcomes for cancer patients. More information is available at www.iovance.com.
Amtagvi®, Proleukin®, Iovance®, and IovanceCares™ are either trademarks or registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. Other trademarks referenced are the property of their respective owners.
Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Terms such as “predicts,” “believes,” “potential,” and “anticipates” indicate uncertainty regarding future events or outcomes and are meant to identify forward-looking statements. These statements rely on various assumptions and assessments based on management’s historical perceptions, current conditions, expectations of future developments, and other relevant factors.
Forward-looking statements reflect the Company’s views as of the release date, and Iovance Biotherapeutics does not commit to update these statements in light of new information or future events. These statements are not guarantees of future performance and come with risks and uncertainties that could lead to actual results differing significantly. Important factors potentially impacting results are detailed in “Risk Factors” sections of Iovance’s filings with the U.S. Securities and Exchange Commission, including in their most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Risks include challenges in commercializing their products, regulatory approvals, market acceptance, manufacturing capabilities, and the impact of external factors such as global market conditions.
Contacts
Iovance Biotherapeutics, Inc:
Sara Pellegrino, IRC
Senior Vice President, Investor Relations & Corporate Communications
650-260-7120 ext. 264
[email protected]
Jen Saunders
Senior Director, Investor Relations & Corporate Communications
267-485-3119
[email protected]
This article was originally published on Quiver News; read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
